DOSAGE REGIMENS FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY IN COMBINATION WITH CHEMOTHERAPY

The present invention relates to dosage regimens for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) in combination with paclitaxel, and their medical use in the treatment of squamous cell carcinoma of the head and nec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MULLINS, Stefanie, PATKI, Abhay, READER, Claire, MORROW, Michelle
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to dosage regimens for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) in combination with paclitaxel, and their medical use in the treatment of squamous cell carcinoma of the head and neck in human patients. La présente invention concerne des régimes posologiques pour l'administration d'une molécule d'anticorps qui se lie au ligand de mort programmée 1 (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) en combinaison avec le paclitaxel, et leur utilisation médicale dans le traitement du carcinome à cellules squameuses de la tête et du cou chez des patients humains.